3 Dividend Stocks for May 2026

By Morningstar, Inc.

Share:

Key Concepts

  • Dividend Yield: The annual dividend payment divided by the stock's current price.
  • Dividend Aristocrat: A company that has increased its dividend payout for at least 25 consecutive years.
  • Fair Value Estimate: Morningstar’s assessment of a stock's intrinsic value based on long-term cash flow projections.
  • Star Rating: A Morningstar metric (1 to 5 stars) indicating whether a stock is undervalued (4-5 stars) or overvalued (1-2 stars) relative to its fair value.
  • Free Cash Flow (FCF): The cash a company generates after accounting for cash outflows to support operations and maintain capital assets.

Pfizer (PFE)

Financial Outlook and Dividend Analysis

  • Current Status: Pfizer currently offers a 6.6% dividend yield, significantly higher than its 5-year average of 4.5%.
  • Dividend Growth: The company has seen modest growth of 2.5% annualized over the last five years. Notably, it broke a streak of annual increases dating back to 2011 by failing to provide a raise in the first quarter of 2026.
  • Growth Constraints: Morningstar analysts project challenges in top- and bottom-line growth due to patent expirations. Long-term dividend growth is expected to remain in the low single digits, supported by steady free cash flows from a diversified portfolio.
  • Projections: The current annual dividend of $1.72 is forecasted to reach $1.80 by 2029.
  • Valuation: Trading at a 15% discount to its $32 fair value estimate, the stock is currently rated as a four-star investment.

Sysco (SYY)

Operational Strategy and Debt Impact

  • Track Record: As the largest U.S. food service distributor, Sysco maintains "Dividend Aristocrat" status with 56 consecutive years of dividend increases.
  • Performance: The stock yields 3%, with a 3.5% annualized dividend growth rate over the past five years.
  • Strategic Developments: The acquisition of Jetro Restaurant Depot is viewed as a long-term value driver. However, the debt load incurred to finance this purchase is expected to constrain dividend growth in the near term.
  • Valuation: Trading at a >10% discount to its $84 fair value estimate, Sysco holds a four-star rating.
  • Notable Quote: During the January 27th earnings call, the CFO stated: "We are proud of our strong track record of dividend growth and dividend aristocrat status."

Watsco (WSO)

Capital Allocation and Cash Flow Coverage

  • Dividend Growth: Watsco, the largest HVAC and refrigeration distributor in North America, recently announced a 10% dividend increase. It has raised payouts for 12 consecutive years (following a 2013 cut) and boasts an 11.1% annualized growth rate over the last five years.
  • Yield: The current yield of 3.1% is above its 5-year average of 2.7%.
  • Capital Allocation Philosophy: Unlike many peers, Watsco does not repurchase shares. Due to significant insider ownership by a single family, the company prioritizes dividend payments.
  • Financial Health: Although the annual dividend rate has exceeded earnings per share (EPS) for the past three years, Morningstar analysts emphasize that the dividend remains well-covered by cash flow.
  • Projections: The current annual rate of $13.20 is forecasted to grow to $19.33 by 2030.
  • Valuation: Despite exceeding Q1 estimates, the stock price dropped 5% following the April 28th release. It currently trades at a modest discount to fair value, resulting in a three-star rating.

Synthesis and Conclusion

The three companies analyzed represent different stages of dividend maturity and strategic focus. Pfizer is currently a high-yield play facing structural growth headwinds due to patent cliffs. Sysco remains a reliable, long-term income generator, though its recent acquisition activity has temporarily limited its ability to aggressively raise dividends. Watsco stands out for its aggressive dividend growth and family-led capital allocation policy that favors shareholders over buybacks, despite a higher payout ratio relative to earnings. Investors should weigh the high yields of Pfizer and Watsco against the potential for near-term volatility and the debt-related constraints currently impacting Sysco.

Chat with this Video

AI-Powered

Load the transcript when you're ready to chat so the initial page stays lighter.

Related Videos

Ready to summarize another video?

Summarize YouTube Video